Open AccessEndometrial Carcinoma Insensitive to Progestin and Cytotoxic Chemotherapy May Respond to Tamoxifen
Author(s) -
Kauppila A.,
Vihko R.
Publication year - 1981
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348109155493
Subject(s) - medicine , antiestrogen , progestin , tamoxifen , chemotherapy , endometrial cancer , carcinoma , oncology , estrogen , endometrium , estrogen receptor , cytotoxic t cell , cancer research , cancer , breast cancer , biology , biochemistry , in vitro
Estrogen and progestin receptor‐positive endometrial carcinoma, which did not respond with remission to progestin or cytotoxic combination chemotherapy, was sensitive to tamoxifen. This was demonstrated by the complete resolution of pulmonary metastases and pleural effusion, a marked decrease in ESR, and improvement in the general condition of our patient. Although it is very likely that progestin and antiestrogen therapies operate by similar molecular mechanisms, they may be complementary.